Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials-Reference-Cited by-同舟云学术

Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials

Published:2001-10 Issue:5 Volume:22 Page:485-502
ISSN:0197-2456
Container-title:Controlled Clinical Trials
language:en
Short-container-title:Controlled Clinical Trials

Author:

De Gruttola Victor G,Clax Pamela,DeMets David L,Downing Gregory J,Ellenberg Susan S,Friedman Lawrence,Gail Mitchell H,Prentice Ross,Wittes Janet,Zeger Scott L

Publisher

Elsevier BV

Subject

Pharmacology

Reference18 articles.

1. Biomarkers and surrogate endpoints;Clinical Pharmacol Ther,2001

2. Surrogate endpoints in clinical trials;Prentice;Stat Med,1998

3. Statistical validation of intermediate endpoints for chronic diseases;Freedman;Stat Med,1992

4. Modeling the relationship of survival to longitudinal data measured with error. Applications to survival and CD4 counts in patients with AIDS;Tsiatis;J Am Stat Assoc,1995

5. Meta-analysis for the evaluation of potential surrogate markers;Daniels;Stat Med,1997

Cited by 335 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dendrimer-mediated targeting of angiogenic biomarkers: therapeutic intervention against cancer;Expert Opinion on Drug Delivery;2024-09-04

2. Low-density lipoprotein cholesterol is not a successful surrogate endpoint: author’s reply;Journal of Clinical Epidemiology;2024-07

3. Personalized anesthesia and precision medicine: a comprehensive review of genetic factors, artificial intelligence, and patient-specific factors;Frontiers in Medicine;2024-05-09

4. Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity;Statistical Methods in Medical Research;2024-05-08

5. Considerations for open-label randomized clinical trials: Design, conduct, and analysis;Clinical Trials;2024-04-15